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Multiple Sclerosis (MS) is a chronic autoimmune disease of the Central Nervous System causing inflammation and neurode-
generation. There are only 3 epidemiological studies in Portugal, 2 in the Centre and 1 in the North, and there is the need to
further study MS epidemiology in this country. The objective of this work is to contribute to the MS epidemiological knowledge in
Portugal, describing the patients’ epidemiological, demographic, and clinical characteristics in the Braga district of Portugal. This
is a cross-sectional study of 345 patients followed in two hospitals of Braga district. These hospitals cover a resident population of
866,012 inhabitants. The data was collected from the clinical records, and 31/12/2009 was established as the prevalence day. For all
MS patients, demographic characteristics and clinical outcomes are reported. We have found an incidence of 2.74/100,000 and a
prevalence of 39.82/100,000 inhabitants. Most patients have an EDSS of 3 or lower and a mean age of 42 years. The diagnosis was
done at mean age of 35, with RRMS being the disease type in more than 80% of patients. In this cohort, we found a female :male
ratio of 1.79. More than 50% of patients are treated with Interferon 𝛽-1b IM or IFN𝛽-1a SC 22 𝜇g.
1. Introduction
Multiple Sclerosis (MS) is a chronic autoimmune disease of
theCentralNervous System (CNS) causing inflammation and
neurodegeneration. The characteristic demyelination of the
neurons, followed in many cases by axonal loss and gliosis,
results in incapacity progression [1]. The incapacity status is
usually assessed in MS patients with the Expanded Disability
Status Scale (EDSS) [2]. Different types of MS have been
described based on the clinical course: Relapsing-Remitting
Multiple Sclerosis (RRMS), Secondary Progressive Multiple
Sclerosis (SPMS), Primary Progressive Multiple Sclerosis
(PPMS), Relapsing-Progressing Multiple Sclerosis (RPMS)
[3] and Clinically Isolated Syndrome (CIS) [4].
There is yet no cure forMS, but several disease modifying
treatments have shown to have beneficial effects on the dis-
ease progression. The approved treatments for MS in Europe
include Interferon 𝛽-1a SC and IM, Interferon 𝛽-1b SC, Glati-
ramer Acetate SC, Natalizumab IV, oral Fingolimod, oral Di-
methyl Fumarate, oral Teriflunomide, and Alemtuzumab IV.
MS has a great social and economic impact, because it
affects mainly young adults [5], who will be more prone to
unemployment [6] and in a big percentage will need a walk-
ing aid few years after the disease onset [7, 8]. MS is more
prevalent in females [9] and Caucasians [10] and it is influen-
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Table 1: Age at diagnosis.
Minimum Maximum Mean Median Std. deviation 1st Q 3rd Q
Total 13,61 70,55 35,38 34,91 11,58 26,09 42,24
HSM 14,82 70,55 36,09 35,84 11,75 26,98 44,41
HSO 13,61 65,83 33,84 33,22 11,10 25,72 39,85
The mean age at diagnosis is 35.
Table 2: Most of patients have the Relapsing-Remitting form of Multiple Sclerosis.
MS form HSM HSO Total
𝑛 % 𝑛 % 𝑛 %
CIS 2 0,85% 1 0,91% 3 0,87%
RRMS 190 80,85% 96 87,27% 286 82,90%
SPMS 37 15,74% 12 10,91% 49 14,20%
PPMS 6 2,55% 1 0,91% 7 2,03%
Total 235 110 345
Our aim is to contribute to the MS epidemiological kno-
wledge in Portugal, describing the patients’ epidemiological,
demographic, and clinical characteristics.
2. Methods
The district of Braga is located in the Northwestern part of
Portugal. In the district of Braga, there are two hospitals with
consultation and treatment of multiple sclerosis for a resident
population of 866,012 inhabitants (INE). The hospitals are
Hospital de São Marcos in the city of Braga (HSM) and Hos-
pital Senhora da Oliveira in the city of Guimarães (HSO).
Braga is the youngest district of Portugal: 30.7% of the pop-
ulation is under 25 years, 56.4% are between 25 and 64 years,
and 12.9% have more than 64 years. The population of this
district is mostly lower middle class (which covers 37.1% of
the population).
This is a cross-sectional study of MS patients followed in
the Braga and Guimarães Hospitals. The data was collected
from the clinical records, and 31/12/2009 was established as
the prevalence day. At the prevalence date, only Interferon
𝛽-1a SC and IM, Interferon 𝛽-1b SC, Glatiramer Acetate SC,
and Natalizumab IV were approved for MS in Europe. All
the cases were assessed by a neurologist and included in the
study whenever they met the Poser diagnostic criteria. Only
residents of Braga district which had an office visit between
the 1st of January 1997 and the 31st of December 2009 were
included in this study. We requested the necessary consent
to patients, Portuguese Data Privacy Committee (Comissão
Nacional de Proteção de Dados), and to the Ethical Com-
mittees of both hospitals. There were no clinical records for
HSM patients before 1997. In order to compare the hospitals,
the year of diagnosis for HSO patients was considered to be
1997 for every patient that had records older than that.
In this study, for all MS patients, demographic character-
istics (sex, age, age at diagnosis, treatment, and spatial dis-
tribution of place of residence) and clinical outcome (type of
the disease, treatment, clinical severity score [EDSS], and year
and month of diagnosis) are reported. Student’s 𝑡-test and
Chi-squared test were used to evaluate differences between
groups. All significance tests were based on 𝑃 < 0.05 as the
level of significance.
3. Results
Thedatabase is composed of 345 individuals that are followed
in the MS outpatient clinic of HSM and HSO. The estimated
disease prevalence is 39.84 per 100,000 inhabitants (95%CI =
27.47–52.21). The female :male ratio is 1.79, with 64.06% of
females MS patients and 35.94% males.
The mean age at diagnosis is approximately 35 years and
varies between 13.61 and 70.55 years (Table 1). At prevalence
day, the mean age is 42.
HSMandHSOhave a similar distribution of patients over
the RRMS and SPMS forms. The number of patients with
PPMS and CIS forms is too low be compared between hos-
pitals (Table 2).
The most common treatment is Interferon 𝛽-1b IM, with
29.86%, followed by IFN𝛽-1a SC 22𝜇g with 24.64%, Glati-
ramer Acetate with 17.97%, IFN𝛽-1a SC 44 𝜇g with 12.17%,
IFN𝛽-1a IMwith 7.25%, Natalizumab IVwith 5.51%, andMit-
oxantrone 0.29%. 2.32% of patients are without treatment
(Figure 1).
Patients were divided in three groups according to their
disability as quantified by the EDSS. Most patients have an
EDSS of 3 or less (Figure 2).
In HSM, there were no MS patient records before 1997.
HSOMS patients have records for previous years, but we dec-
ided to consider 1997 as the year of diagnosis in those cases.
If we assume 866,012 as the Braga district population from
1998 to 2009, we can estimate an average annual incidence of
2.74/100,000 inhabitants in the Braga district (Figure 3).
4. Discussion
MS patients in Portugal are almost exclusively followed
in public hospitals because Disease Modifying Treatments





















































































































Figure 2: The patient distribution in these three EDSS groups is
similar in both hospitals (𝑃 = 0.0549).
(DMTs) are almost only offered to patients without any copa-
yment in the National Health System (NHS) hospitals. As a
result, only a very small number of patients, at national level,
have access to DMTs outside the NHS hospitals. HSM and
HSOare the onlyMS reference centers in the district of Braga,
so it is expected that the vast majority of MS patients of this
district be registered in one of these two hospitals. There is
the possibility that some MS patients from this district are
followed in other MS centers in Portugal, so the estimated
prevalencemay be underestimated. Tomore accurately deter-
mine the MS prevalence in this district, further work should












































Figure 3: The annual incidence between 1998 and 2009 was
2.74/100,000.
care centers patient’s lists would give themost accurate preva-
lence numbers. Additionally,MS patient’s lists, fromhospitals
like Centro Hospitalar de São João, Centro Hospitalar do
Porto, and Centro Hospitalar e Universitário de Coimbra
should be checked to capture patients with residence in Braga
district, who are followed in those hospitals.
For several years, Portugal has been considered to be a
low-mediumprevalence zone forMS [11], but recent epidemi-
ological studies suggest that our country should instead be
considered a medium prevalence zone [12, 13]. A prevalence
study in the district of Santarém [13] determined a prevalence
of 46.3 cases/100,000 in 2006 and a nationwide survey
presented in 2011 by J. Pinheiro found this number to be
54/100,000 [14].More recently, a prevalence study in a referral
hospital and three community health clinics in a large city
(Lisboa) determined a prevalence of 56.2/100,000 [15]. The
39.84/100,000 prevalence that we estimated in this study is
probably underestimated due to the exclusion of patients who
are resident in Braga district but are followed in other hos-
pitals from cities like Oporto or Coimbra. The 2.74/100,000
annual incidence is lower than that reported for Spain and
Italy [16], but this value is probably underestimated for the
same reason and also because we considered a constant pop-
ulation (equal to 2009 numbers) between 1998 and 2009.
The gender ratio F :M in this study is 1.79. In both hos-
pitals, the highest number of diagnosis was in the year 2008
(excluding 1997) with 11.88% of the patients.TheMS diagnos-
tic of HSO patients wasmade at a younger age.The age at dia-
gnosis, patient distribution amongst MS forms, and disab-
ility status assessed by EDSS is also consistent with the results
from previousMS studies [7, 16].The low percentage of patie-
nts without treatment, 2.32%, is noteworthy.
5. Conclusion
Thedistrict of Braga is amediumprevalence zone forMSwith
a prevalence of 39.82/100,000 inhabitants. We estimated an
average annual incidence of 2.74/100,000 inhabitants between
1998 and 2009. In this study, MS patients’ demographic and
4 Neurology Research International
clinical characteristics are consistent with what was expected
in light of current scientific literature.
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Highlights
(i) 345MS patients followed in Braga district and (ii) patient’s
demographic characteristics (sex, age, age at diagnosis, treat-
ment, and spatial distribution of place of residence) and clin-
ical outcome (type of the disease, treatment, clinical severity
score [EDSS], and year and month of diagnosis) were collec-
ted.
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